Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715342 | PMC |
| http://dx.doi.org/10.1002/mdc3.13881 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Levodopa-Induced Jaw and Facial Dystonia in a Case of Progressive Supranuclear Palsy with Blepharospasm.
Mov Disord Clin Pract
December 2023
Neurology Clinic, Etlik City Hospital Ankara Turkey.
Moving chin left and right: levodopa induced dyskinesia in spinocerebellar ataxia type 3?
Acta Neurol Belg
December 2023
Department of Neurology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, N1 Shangcheng Avenue, Yiwu, 322000, Zhejiang, China.
Levodopa-induced lateral jaw deviation dystonia.
Parkinsonism Relat Disord
July 2015
Department of Neurology, University of Tennessee Health Science Center, 855 Monroe Avenue, Memphis, TN 38163, USA.
Site of deep brain stimulation and jaw velocity in Parkinson disease.
J Neurosurg
November 2011
Departments of Integrative Biosciences, Oregon Health & Science University, Portland, Oregon 97201, USA.
Object: While deep brain stimulation (DBS) has proven to be an effective treatment for many symptoms of Parkinson disease (PD), a deterioration of axial symptoms frequently occurs, particularly for speech and swallowing. These unfavorable effects of DBS may depend on the site of stimulation. The authors made quantitative measures of jaw velocity to compare the relative effectiveness of DBS in the globus pallidus internus (GPi) or the subthalamic nucleus (STN).
View Article and Find Full Text PDFA 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Pharmacol Biochem Behav
October 2008
ACADIA Pharmaceuticals Inc., San Diego, CA, USA.
A potent 5-hydroxytryptamine (5-HT)2A receptor inverse agonist and antagonist, ACP-103 [N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1, active:salt)], was evaluated for its ability to reduce the primary motor symptom of tremor using tacrine-induced tremulous jaw movements in rats, which is an animal model of parkinsonian tremor. Furthermore, ACP-103 was evaluated for its ability to reduce levodopa-induced dyskinesias in monkeys rendered parkinsonian with MPTP [1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine]. ACP-103 reduced tacrine-induced tremulous jaw movements in rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!